Gastroenterology Research

Approved: **February 2024**
Study: **ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma (HCC) Test in Subjects with Increased Risk (2021-01)**
Investigator: John Phillips, MD (PI)
Summary: The purpose of this study is to determine the ability of the Oncoguard™ Liver test to accurately and reliably detect hepatocellular carcinoma compared to other methods such as ultrasound, computed tomography, and magnetic resonance imagings.

Approved: **January 2025**
Study: **SWIFT - A Multicenter, Randomized, Double-blind, 2-Part Phase II Study to Evaluate the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (GS-US-409-5704)**
Investigators: Robert Smith, MD (PI); John Phillips, MD
Summary: The purpose of this study is to determine the safety and efficacy of GS-1427 to treat moderate to severe ulcerative colitis.

Approved: **January 2025**
Study: **PALEKONA – A Phase II, Double-blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants with Moderately to Severely Active Ulcerative Colitis (GS-US-457-6411)**
Investigators: Robert Smith, MD (PI); John Phillips, MD
Summary: The purpose of this study is to determine the safety and efficacy of GS-5290 to treat moderate to severe ulcerative colitis.

Approved: **April 2025**
Study: **The ENLIGHTEN-Cirrhosis Study – A Phase III Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (BIO89-100-132)**
Investigators: John Phillips, MD (PI); Robert Smith, MD
Summary: The purpose of this study is to determine the safety, efficacy and long-term outcomes of pegozafermin in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared to placebo.

Approved:	**July 2025**
Study:	**C-BEYOND – Phase III, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) versus Sofosbuvir Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection (AT-01B-007)**
Investigators:	John Phillips, MD (PI); Robert Smith, MD
Summary:	The purpose of this study is to compare the safety and efficacy of bemnifosbuvir-ruzasvir to sofosbuvir-velpatasvir in treating chronic hepatitis C infection.